citalopram has been researched along with clozapine in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (11.90) | 18.2507 |
| 2000's | 19 (45.24) | 29.6817 |
| 2010's | 17 (40.48) | 24.3611 |
| 2020's | 1 (2.38) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Keserü, GM | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Li, Y; Li, YH; Wang, YH; Yang, L; Yang, SL | 1 |
| Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Sen, S; Sinha, N | 1 |
| Atzpodien, EA; Csato, M; Doessegger, L; Fischer, H; Lenz, B; Schmitt, G; Singer, T | 1 |
| Peters, JU | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Buckland, PR; McGuffin, P; Oretti, RG; Spurlock, G | 1 |
| Fischer-Colbrie, R; Kapeller, I; Kroesen, S; Mahata, M; Mahata, SK; Marksteiner, J; Saria, A; Winkler, H | 1 |
| Dekeyne, A; Girardon, S; Gobert, A; Millan, MJ | 1 |
| Ellison, Z; Ementon Shaw, L; Murray, R; Taylor, D; Wickham, H | 1 |
| Morelli, M; Pinna, A | 1 |
| Borba, CP; Henderson, DC | 1 |
| Conca, A; Hubmann, MR; König, P; Moll, W; Waschgler, R | 1 |
| Bajbouj, M; Danker-Hopfe, H; Gallinat, J; Hellen, F; Lang, UE; Lisanby, SH; Neu, P; Vesper, J | 1 |
| Bomsien, S; Skopp, G | 1 |
| Arnt, J; Bang-Andersen, B; Brennum, LT; Christoffersen, CT; Di Matteo, V; Didriksen, M; Esposito, E; Hertel, P; Larsen, AK; Marcus, MM; Pouzet, B; Ramirez, T; Svensson, TH; Søby, KK | 1 |
| Forsberg, S; Helldén, A; Nordberg, P; Sparve, E | 1 |
| Begemann, MJ; Leucht, S; Sommer, IE; Temmerman, A | 1 |
| Haw, C; Stubbs, J | 1 |
| Burns, JD; Green, DM; Schembri, F; Stevenson, E | 1 |
| Lassila, T; Mattila, S; Tolonen, A; Turpeinen, M | 1 |
| Ebrahimzadeh, H; Hosseini, FS; Kharazmi, F | 1 |
3 review(s) available for citalopram and clozapine
| Article | Year |
|---|---|
Polypharmacology - foe or friend?
Topics: Animals; Communicable Diseases; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Polypharmacology; Safety | 2013 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review.
Topics: Antipsychotic Agents; Brief Psychiatric Rating Scale; Citalopram; Clozapine; Dioxoles; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Fructose; Humans; Lamotrigine; Piperidines; Psychiatric Status Rating Scales; Psychotropic Drugs; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Sulpiride; Topiramate; Treatment Outcome; Triazines | 2012 |
2 trial(s) available for citalopram and clozapine
| Article | Year |
|---|---|
Co-administration of citalopram and clozapine: effect on plasma clozapine levels.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Citalopram; Clozapine; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Humans; Middle Aged; Pilot Projects; Schizophrenia | 1998 |
Motor cortex excitability after vagus nerve stimulation in major depression.
Topics: Adult; Benzodiazepines; Citalopram; Clomipramine; Clozapine; Depressive Disorder; Doxepin; Drug Therapy, Combination; Electric Stimulation; Female; Humans; Lamotrigine; Lithium Carbonate; Male; Mianserin; Middle Aged; Mirtazapine; Morpholines; Motor Cortex; Neural Conduction; Neural Inhibition; Olanzapine; Paroxetine; Psychiatric Status Rating Scales; Reboxetine; Tranylcypromine; Triazines; Vagus Nerve; Valproic Acid | 2007 |
37 other study(ies) available for citalopram and clozapine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
Topics: Computational Biology; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Molecular Structure; Principal Component Analysis; Pyrrolizidine Alkaloids; Quantitative Structure-Activity Relationship; Reproducibility of Results; Substrate Specificity; Venlafaxine Hydrochloride | 2005 |
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats | 2007 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
Topics: Animals; Cattle; Cells, Cultured; Computer Simulation; Cornea; Drug-Related Side Effects and Adverse Reactions; Fibroblasts; Lipidoses; Lysosomal Storage Diseases; Models, Molecular; Pharmaceutical Preparations; Phospholipids; Structure-Activity Relationship; Thermodynamics | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Lack of effect of antipsychotic and antidepressant drugs on glutamate receptor mRNA levels in rat brains.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Base Sequence; Brain Chemistry; Citalopram; Clozapine; Gene Expression Regulation; Haloperidol; Male; Mianserin; Molecular Sequence Data; Nerve Tissue Proteins; Rats; Rats, Wistar; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Schizophrenia; Sulpiride | 1994 |
Effects of haloperidol, clozapine and citalopram on messenger RNA levels of chromogranins A and B and secretogranin II in various regions of rat brain.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Brain; Chromogranins; Citalopram; Clozapine; Haloperidol; Male; Proteins; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tissue Distribution | 1995 |
Citalopram elicits a discriminative stimulus in rats at a dose selectively increasing extracellular levels of serotonin vs. dopamine and noradrenaline.
Topics: Animals; Biogenic Monoamines; Cerebral Cortex; Citalopram; Clozapine; Corpus Striatum; Diazepam; Dopamine; Dose-Response Relationship, Drug; Extracellular Space; GABA Agents; Male; Norepinephrine; Nucleus Accumbens; Paroxetine; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline | 1999 |
Antidepressants and atypical neuroleptics induce Fos-like immunoreactivity in the central extended amygdala.
Topics: Amygdala; Animals; Antidepressive Agents; Antipsychotic Agents; Citalopram; Clozapine; Gene Expression Regulation; Genes, fos; Haloperidol; Imipramine; Male; Neurons; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley | 1999 |
Citalopram and clozapine: potential drug interaction.
Topics: Adult; Citalopram; Clozapine; Confusion; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Fatigue; Humans; Male; Psychotic Disorders; Sialorrhea; Sleep Wake Disorders | 2000 |
Simultaneous quantification of citalopram, clozapine, fluoxetine, norfluoxetine, maprotiline, desmethylmaprotiline and trazodone in human serum by HPLC analysis.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Chromatography, High Pressure Liquid; Citalopram; Clozapine; Fluoxetine; Humans; Maprotiline; Trazodone | 2002 |
An in vitro approach to potential methadone metabolic-inhibition interactions.
Topics: Algorithms; Amitriptyline; Analgesics, Opioid; Atomoxetine Hydrochloride; Chromatography, Liquid; Citalopram; Clozapine; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Isoenzymes; Kinetics; Methadone; Methylation; N-Methyl-3,4-methylenedioxyamphetamine; Oxidoreductases, N-Demethylating; Propylamines; Psychotropic Drugs; Pyridines; Pyrrolidines; Tandem Mass Spectrometry; Zolpidem | 2007 |
Lu 35-138 ((+)-(S)-3-{1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)ethyl]-3,6-dihydro-2H-pyridin-4-yl}-6-chloro-1H-indole), a dopamine D4 receptor antagonist and serotonin reuptake inhibitor: characterisation of its in vitro profile and pre-clinical antipsych
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Animals, Outbred Strains; Benzodiazepines; Cebus; Citalopram; Clozapine; Cognition; Dihydropyridines; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Haloperidol; Haplorhini; Humans; Indoles; Male; Mice; Molecular Structure; Motor Activity; Olanzapine; Piperazines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Dopamine D4; Risperidone; Selective Serotonin Reuptake Inhibitors; Sulfonamides | 2007 |
Acute clozapine intoxication.
Topics: Adult; Antipsychotic Agents; Citalopram; Clozapine; Humans; Male; Pneumonia, Aspiration; Schizophrenia, Paranoid | 2009 |
Medication for borderline personality disorder: a survey at a secure hospital.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Borderline Personality Disorder; Citalopram; Clozapine; Data Collection; Female; Guidelines as Topic; Hospitals, Psychiatric; Humans; Inpatients; Male; Middle Aged; Off-Label Use; Polypharmacy; Practice Patterns, Physicians'; United Kingdom | 2011 |
Serotonin syndrome associated with clozapine withdrawal.
Topics: Benzodiazepines; Citalopram; Clozapine; Cyproheptadine; Female; Humans; Middle Aged; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Syndrome; Substance Withdrawal Syndrome | 2013 |
Glutathione trapping of reactive drug metabolites produced by biomimetic metalloporphyrin catalysts.
Topics: Citalopram; Clozapine; Glutathione; Humans; Metalloporphyrins; Microsomes, Liver; Oxidation-Reduction; Tandem Mass Spectrometry; Ticlopidine | 2015 |
Polyvinyl alcohol/citric acid/β-cyclodextrin/CuONP composite nanofibers as an effective and green absorbent for the simultaneous extraction of three antidepressant drugs in biological fluids prior to GC-FID analysis.
Topics: Antidepressive Agents; beta-Cyclodextrins; Chromatography, Gas; Citalopram; Clozapine; Imipramine; Nanofibers; Polyvinyl Alcohol; Spectroscopy, Fourier Transform Infrared | 2023 |